ArticleNature communications2023
Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir.
Xiangrui Jiang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
58 papers cite it
this papertrialcites it